By Fineline Cube 
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced a licensing agreement with Unilab, Inc., granting the Philippine pharma regulatory filing and commercialization rights to its Mailishu (9MW0311) and Maiweijian (9MW0321), biosimilars of denosumab, in the Philippines. Under the agreement, Mabwell retains responsibility for development, manufacturing, and commercial supply.
Global Expansion and Manufacturing Excellence
Mabwell has secured denosumab partnerships in Brazil, Colombia, Indonesia, Singapore, Pakistan, Thailand, Egypt, and Saudi Arabia. The company’s manufacturing facilities have passed the Colombian INVIMA GMP audit, underscoring its commitment to quality and compliance.
Second Collaboration with Unilab
This marks the second collaboration between Mabwell and Unilab, following their 2023 adalimumab biosimilar agreement. The adalimumab biosimilar is currently under marketing review in the Philippines, highlighting the ongoing strategic partnership between the two companies.-Fineline Info & Tech